Skip to main content

Clinical value of PET with Gallium-labelled Radiopharmaceuticals

Edited by:
Asim Afaq, MD, UT Southwestern Medical Center, United States
Shao-Bo Yao, PhD, First Affiliated Hospital of Fujian Medical University, China
 

Submission Status: Open   |   Submission Deadline: 30 June 2025 

This Collection invites researchers to contribute to the growing body of knowledge on the clinical value of PET imaging with Gallium-labelled radiopharmaceuticals. EJNMMI Reports welcomes submissions that explore diagnostic accuracy, clinical applications, and advancements in multidisciplinary clinical assessments, with a focus on enhancing patient outcomes through precision medicine and innovative imaging techniques.

About the collection

Back to top

The use of Gallium-labelled radiopharmaceuticals in Positron Emission Tomography (PET) imaging has emerged as a transformative approach in the field of nuclear medicine, particularly in oncology. These radiopharmaceuticals offer enhanced diagnostic accuracy and specificity for various malignancies, enabling clinicians to better visualize and characterize tumors. The integration of PET with Gallium-labelled agents into clinical practice has not only improved diagnosis and cancer staging but has also facilitated the monitoring of treatment response, thereby enhancing patient management and outcomes. Revolutionary change to clinical practice has been seen with 68Ga-DOTATATE/DOTATOC tracers in neuroendocrine tumors, 68Ga-PSMA  in prostate cancer and more recently potential utility has been described in a range of tumors with 68Ga-FAPI.

Advancing our collective understanding of the clinical value of PET with Gallium-labelled radiopharmaceuticals is crucial for optimizing cancer diagnosis and treatment. Recent advances have demonstrated the potential of these agents in precision medicine, allowing for more prognostic data and personalized therapeutic strategies based on individual tumor biology. Furthermore, studies have shown that Gallium-based imaging can significantly improve the detection of metastases and recurrence, leading to timely interventions. Continued research in this area will help refine imaging protocols and expand the clinical applications of Gallium radioisotopes, ultimately improving patient care.

As research in this field progresses, we can anticipate exciting developments, including the introduction of novel Gallium-labelled compounds with enhanced targeting capabilities and improved pharmacokinetics. These innovations together with other advances in PET imaging may lead to more accurate imaging modalities, including PET/CT and PET/MR, enabling earlier detection of malignancies, guiding management and better assessment of treatment efficacy. Additionally, the integration of artificial intelligence and machine learning in PET imaging has the potential to improve clinical care using these tracers.

Submissions are invited on any aspect of clinical value of PET with Gallium-labelled radiopharmaceuticals, including:

  • Clinical applications of Gallium radioisotopes in oncology
  • Diagnostic accuracy of Gallium PET imaging
  • Advances in PET/CT or PET/MR imaging for cancer staging
  • Potential clinical utility of Gallium labelled PET as imaging biomarkers/ prognostic role
  • Precision medicine and Gallium-labelled radiopharmaceuticals
  • Role of Gallium in monitoring treatment response

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system. During the submission process, under the section additional information, you will be asked whether you are submitting to a Collection, please select "Clinical value of PET with Gallium-labelled Radiopharmaceuticals" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.

There are currently no articles in this collection.